The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity

BMC Musculoskeletal Disorders

Research Article

Massimiliano Parodi¹  Marco A Cimmino¹  Roberto Caporali²  Carlomaurizio Montecucco² 

[1] Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Viale Benedetto XV, 6, 16132, Genova, Italy;IRCCS Policlinico S.Matteo, Pavia, Italy;

关键词: polymyalgia rheumatica;    prednisone;    glucocorticoid;    ultrasonography;   

DOI  :  10.1186/1471-2474-12-94

 received in 2011-01-26, accepted in 2011-05-14,  发布年份 2011

来源: Springer

【 摘 要 】

Backgroundthe mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is no evidence from controlled studies on the efficacy of different initial doses or glucocorticoid tapering. The aim of this study is to test if 12.5 mg prednisone/day is an adequate starting dose in PMR and to evaluate clinical predictors of drug response.Methods60 consecutive PMR patients were treated with a starting dose of 12,5 mg/day prednisone. Clinical, laboratory, and, in a subset of 25 patients, ultrasonographic features were recorded as possible predictors of response to prednisone. Remission was defined as disappearance of at least 75% of the signs and symptoms of PMR and normalization of ESR and CRP within the first month, a scenario allowing steroid tapering.Results47/60 (78.3%) patients responded to 12.5 mg of prednisone after a mean interval of 6.6 ± 5.2 days. In univariate analysis, body weight and gender discriminated the two groups. In multivariate analysis, the only factor predicting a good response was low weight (p = 0.004); the higher response rate observed in women was explained by their lower weight. The mean prednisone dose per kg in the responders was 0.19 ± 0.03 mg in comparison with 0.16 ± 0.03 mg for non responders (p = 0.007).Conclusions12.5 mg prednisone is a sufficient starting dose in ¾ of PMR patients. The main factor driving response to prednisone in PMR was weight, a finding that could help in the clinical care of PMR patients and in designing prospective studies of treatment.Trial RegistrationClinicalTrials.gov: NCT01169597

【 授权许可】

CC BY   
© Cimmino et al; licensee BioMed Central Ltd. 2011